Medical AI startup Promedius announced its participation in the Pre-Competitive Consortium on Osteoporosis and Bone Health (PRECCO), a new industry-academia collaboration that will play an important role in bone health and osteoporosis management. PRECCO is part of a multi-year partnership between the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the World Health Organization (WHO), bringing together academia and industry to improve the epidemiology, screening, diagnosis, prevention and treatment of osteoporosis and fracture, and to raise awareness of the disease.

PRECCO is currently working with the Qatar Ministry of Health to strengthen osteoporosis management at the national level, and continues to engage with various stakeholders, focusing on osteoporosis patients. Meanwhile, the WHO is conducting a number of studies, including a "A systematic review of valid and reliable tools to assess the quality of life in older persons with osteoporosis and sarcopenia." and "A cost and benefit analysis on interventions for preventing fractures in older persons using one health tool," in which Promedius' technology is expected to provide important insights. PRECCO includes world-renowned pharmaceutical and biotech companies such as Theramex, Celltrion, and osteolabs.

By joining this collaboration, Promedius will be able to contribute to the early diagnosis of osteoporosis and the prevention of fractures. Together, they will develop guidance on how to use data to strengthen national health information systems and design policies and programs to reduce fracture risk in older adults. The initiative is the culmination of more than seven years of hard work by the ESCEO and the collaboration of sponsors to convince the WHO to recognize osteoporosis as a condition that needs to be carefully managed, further signifying the importance of Promedius’ participation in PRECCO.

"We are pleased to play an important role in contributing to early diagnosis and fracture prevention by leveraging opportunistic screening, a relatively new approach in the industry," said Hyunjin Bae, CEO of Promedius. "We will continue to advance our AI solutions for the early detection and management of musculoskeletal diseases, including osteoporosis.”